Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
1. A method for treating a human subject having an acid sphingomyelinase deficiency (ASMD), comprising:
(a) administering at least one initial dose of recombinant human acid sphingomyelinase (rhASM) to the human subject, wherein the initial dose is from 0.025 mg/kg to 0.275 mg/kg; and
(b) if the plasma ceramide concentration of the human subject is equal to or less than 10 μg/mL after the administration of the at least one initial dose, administering a higher dose of rhASM to the human subject.
2. A method for treating a human subject having an acid sphingomyelinase deficiency (ASMD), comprising:
(a) administering at least one initial dose of recombinant human acid sphingomyelinase (rhASM) to the human subject, wherein the initial dose is from 0.025 mg/kg to 0.275 mg/kg; and
(b) if the total bilirubin concentration of the human subject is equal to or less than 1.5 mg/dL after the administration of the at least one initial dose, administering a higher dose of rhASM to the human subject.
3. A method for treating a human subject having an acid sphingomyelinase deficiency (ASMD), comprising:
(a) administering at least one initial dose of recombinant human acid sphingomyelinase (rhASM) to the human subject, wherein the initial dose is from 0.025 mg/kg to 0.275 mg/kg; and
(b) if the plasma C-reactive protein (CRP) concentration of the human subject is equal to or less than 12 mg/L after the administration of the at least one initial dose, administering a higher dose of rhASM to the human subject.
4. The method of any one of claims 1 - 3 , wherein the higher dose is from 0.1 mg/kg to 1 mg/kg, 0.5 mg/kg to 2 mg/kg, or 2 mg/kg to 4 mg/kg higher than the one or more initial doses.
5. The method of any one of claims 1 - 3 , wherein each dose is administered one, two, three, or four weeks after the previous dose.
6. The method of any one of claims 1 - 3 , wherein the doses are administered intravenously, intradermally, subcutaneously, or intramuscularly.
7. The method of any one of claims 1 - 3 , wherein the acid sphingomyelinase deficiency is Niemann Pick Disease (NPD) type A.
8. The method of any one of claims 1 - 3 , wherein the acid sphingomyelinase deficiency is NPD type B.
9. The method of any one of claims 1 - 3 , wherein the human subject has a missense mutation in the gene encoding acid sphingomyelinase.
10. The method of claim 9 , wherein the mutation is L302P, H421Y, or R496L.
11. The method of any one of claims 1 - 3 , wherein the human subject has a mutation in the gene encoding acid sphingomyelinase and the mutation is ΔR608.
12. The method of any one of claims 1 - 3 , wherein the ASMD is a non-neuronopathic ASMD.
13. The method of claim 3 , wherein the CRP is high sensitivity CRP (hs-CRP).